Showing results (251-260 of 315) with videos related to
Sort By:
Pageof 32
Blood|October 9, 2009
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow TransplantationNicolaus Kröger, Ernst Holler, Guido Kobbe, et al.Haematologica|June 25, 2026
Prognostic impact of t(9;11) and del(7q) as intermediate-risk abnormalities in acute myeloid leukemia following allo-transplant: an Acute Leukemia Working Party study from the European Society for Blood and Marrow TransplantationIman Abou Dalle, Jacques-Emmanuel Galimard, Ali Bazarbachi, et al.Blood Advances|December 3, 2021
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristicsMehdi Hamadani, Maud Ngoya, Anna Sureda, et al.Cancer|October 24, 2018
Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working PartyAli Bazarbachi, Ariane Boumendil, Hervé Finel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2016
Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow TransplantationJan Styczynski, Gloria Tridello, Lidia Gil, et al.British Journal of Haematology|June 8, 2017
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)Johannes Schetelig, Liesbeth C de Wreede, Niels S Andersen, et al.Journal for Immunotherapy of Cancer|April 18, 2023
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working PartyOlaf Penack, Christophe Peczynski, Christian Koenecke, et al.Journal of Hematology & Oncology|February 21, 2026
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working partyEvgenii Shumilov, Maud Ngoya, Philipp Berning, et al.Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.American Journal of Hematology|November 28, 2024
Methotrexate Versus Mycophenolate Mofetil Prophylaxis in Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Malignancies: A Retrospective Analysis on Behalf of the Chronic Malignancies Working Party of the EBMTThomas Luft, Luuk Gras, Linda Koster, et al.Pageof 32